Eurofins Scientific SEERFSF -2.40%76 5-Year Yield-on-Cost % is 1.07 as of Jul. 03, 2026, which is 51% above its 10-year median of 0.71. GuruFocus rates ERFSF with a GF Score™ of 76/100 and a GF Value™ of $75.15 (Fairly Valued). The stock has 7 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 73.44% on this metric.
Eurofins Scientific SE's yield on cost for the quarter that ended in Dec. 2025 was 1.07.
The historical rank and industry rank for Eurofins Scientific SE's 5-Year Yield-on-Cost % or its related term are showing as below:
ERFSF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.26 Med: 0.71 Max: 2.2
Current: 1.07
During the past 13 years, Eurofins Scientific SE's highest Yield on Cost was 2.20. The lowest was 0.26. And the median was 0.71.
ERFSF's 5-Year Yield-on-Cost % is ranked worse than 73.44% of 64
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.44
vs ERFSF: 1.07
Eurofins Scientific SE (OTCPK:ERFSF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Eurofins Scientific SE 5-Year Yield-on-Cost % Related Terms
ERFSF vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's 5-Year Yield-on-Cost % falls into.
Eurofins Scientific SE 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Eurofins Scientific SE (ERFSF) has a 5-Year Yield-on-Cost % of 1.07 as of Jul. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Eurofins Scientific SE and its competitors. This is 51% above median its historical median of 0.71. Over the past decade, Eurofins Scientific SE's 5-Year Yield-on-Cost % has ranged from 0.26 to 2.20. According to the industry distribution chart, Eurofins Scientific SE ranks #47 out of 64 companies in the Medical Diagnostics & Research industry, placing it in the top 73.4%.
Is Eurofins Scientific SE's 5-Year Yield-on-Cost % too high?
Eurofins Scientific SE's current 5-Year Yield-on-Cost % of 1.07 is 51% above median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 2.20. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.44. Eurofins Scientific SE's value of 1.07 is 56.1% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #47 out of 64 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #47 out of 64 companies for 5-Year Yield-on-Cost %. This places Eurofins Scientific SE in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. Eurofins Scientific SE's value of 1.07 is 56.1% below this benchmark. Historically, Eurofins Scientific SE's own 5-Year Yield-on-Cost % has ranged from 0.26 to 2.20 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 2.44, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.44, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current 5-Year Yield-on-Cost % of 1.07 is 56.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current 5-Year Yield-on-Cost % is 1.07, which is 51% above median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $75.15, compared to a current price of $77.54 — trading 3.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.07, which is 51% above median its 10-year median of 0.71 and 56.1% below the Medical Diagnostics & Research industry median of 2.44. Eurofins Scientific SE's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current 5-Year Yield-on-Cost % is 1.07 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $77.54 is trading 3.2% above its estimated GF Value™ of $75.15.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
5-Year Yield-on-Cost %: 1.07 (51% above median its 10-year median of 0.71)
GF Value™: $75.15 vs. price of $77.54 (3.2% above fair value)
Industry Position: 56.1% below the Medical Diagnostics & Research median (#47 of 64)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
76GF Score
Get the complete analysis for ERFSF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 